Option Care Health, Inc. · NASDAQ:OPCH

Option Care Health — Investor Presentation (November 2025)

17 slides from Option Care Health's investor presentation, November 2025

1. Slide 1: Investor Presentation November 2025

   INVESTOR PRESENTATION NOVEMBER 2025 © 2025 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED

2. Slide 2: Disclaimers

   Disclaimers Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “pla

3. Slide 3: Option Care Health is a leading independent provider of home and alternate site infusion services

   Option Care Health is a leading independent provider of home and alternate site infusion services 285,000+ o Our mission: Transform healthcare by Patients Served in 2024 providing innovative services that improve outcomes, reduce 5,000+ overall costs of care and deliver hope for patients and familie

4. Slide 4: Investment Highlights

   Investment Highlights 1 Favorable Position in a Large and Growing Industry On the Right Side of Healthcare: High Quality at an Appropriate Cost in a Patient- 2 Centric Setting 3 Well-Diversified Portfolio of Therapies and Payer Relationships 4 Strong Core Values that Drive Patient Satisfaction 5 Pro

5. Slide 5: Strong Performance and Significant Progress in Q3

   Strong Performance and Significant Progress in Q3 Balanced growth across the therapy portfolio translated Raised full year 2025 guidance based on continued to strong Q3 earnings performance1 strong performance2  Net Revenue of $1,435.0 million, +12.2%  Net revenue $5.60 billion to $5.65 billion 

6. Slide 6: Uniquely Positioned to Capture Growing Demand

   Uniquely Positioned to Capture Growing Demand o Fragmented provider landscape within home infusion industry enables a wide range of HOME OPCH $100B growth opportunities U.S. Home INFUSION Total U.S. Infusion LANDSCAPE1 Infusion Other o National independent platform helps enable Providers economies o

7. Slide 7: Robust National Platform with Comprehensive Clinical Solutions

   Robust National Platform with Comprehensive Clinical Solutions Referral Referral Source Rx+DWO Rx+DWO Hospital Physician Office/Clinic Service Model Pharmacy/CMC Licensed Practitioner Place of Administration Home Infusion Suite Infusion Clinic Home and Alternate Site Infusion Model Infusion Clinic M

8. Slide 8: Valuable Tech-Enabled Platform Across Stakeholder Spectrum

   Valuable Tech-Enabled Platform Across Stakeholder Spectrum  Consistent and reliable  Assist in managing total  High-quality care in a  Provide expert clinical Pharma Health Systems Patients Payers services to help health cost of care with convenient place of capabilities, broad systems transitio

9. Slide 9: Durable and Resilient Revenue Base

   Durable and Resilient Revenue Base Option Care Health operates one integrated network supporting a broad set of therapies, which can be generally categorized as acute and chronic therapies REVENUE COMPOSITION1 Acute Therapies Chronic Therapies o Primarily generic drugs o Branded and biosimilar thera

10. Slide 10: Balanced Revenue and Gross Profit

    Balanced Revenue and Gross Profit 1 REVENUE COMPOSITION PRODUCT MARGIN COMPOSITION2  75%+ of product margin generated by generic and biosimilar therapies that typically have more stable economics Biosimilar Generic Biosimilar  Branded therapies represent ~50% of revenue but <20% of product margin

11. Slide 11: Consistent Record of Growth and Financial Performance

    Consistent Record of Growth and Financial Performance NET REVENUE ADJUSTED EBITDA CASH FLOW FROM OPERATIONS $444M $371M $5.0B $425M $323M $4.3B $343M $3.9B $268M $3.4B $290M $3.0B $209M $222M $127M 7.4% 8.5% 8.8% 9.9% 8.9% 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024 1

12. Slide 12: Strategic Capital Deployment Balances Growth and Return to Shareholders

    Strategic Capital Deployment Balances Growth and Return to Shareholders 2021 – Q3’25 YTD STRATEGIC CAPITAL DEPLOYMENT o Strong and consistent cash generation profile  2021 – Q3’25: $1.4 billion in operating cash flow  Disciplined focus on working capital management $166M o Robust balance sheet and

13. Slide 13: Expectations for the Road Ahead

    Expectations for the Road Ahead  Continue investments in clinical and operational capabilities to leverage national platform with local responsiveness  Deepen partnerships with national and regional payers by utilizing national platform  Continue expansion of portfolio of therapies to include add

14. Slide 14: Contact Us

    Contact Us Our Website investor.relations@optioncare.com investors.optioncarehealth.com © 2025 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 14

15. Slide 15: Reconciliation to Non-GAAP Measures

    Reconciliation to Non-GAAP Measures For historical reconciliations of non-GAAP financial measures, please see our SEC filings and other financial reports, which are available on our website at investors.optioncarehealth.com © 2025 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 15

16. Slide 16: Reconciliation to Non-GAAP Measures

    Reconciliation to Non-GAAP Measures OPTION CARE HEALTH, INC. RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS) (UNAUDITED) Year Ended December 31, 2024 2023 2022 2021 2020 Consolidated net income (loss) $211,823 $267,090 $150,556 $139,898 $ (8,076) Interest expense, net 49,029 51,248

17. Slide 17: Reconciliation to Non-GAAP Measures

    Reconciliation to Non-GAAP Measures For historical reconciliations of non-GAAP financial measures, please see our SEC filings and other financial reports, which are available on our website at investors.optioncarehealth.com © 2025 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 17

Option Care Health — Investor Presentation (November 2025) on 6ix